SCHEDULE: David Lazar Takes Control of Mainz Biomed

Investor David E. Lazar has acquired a 97.4% stake in Mainz Biomed N.V. and has been appointed as the new Chief Executive Officer.

Summary

• David E. Lazar has acquired 5,000,000 Preferred Shares in Mainz Biomed N.V. for a total investment of $6,000,000.
• These shares are convertible into 477,000,000 Ordinary Shares, representing a 97.4% ownership stake in the company.
• Shareholders approved the conversion of these shares and the appointment of David E. Lazar as Executive Director and CEO at the April 22, 2026 meeting.
• The company increased its authorized ordinary shares to 900,000,000 to accommodate the conversion.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly dilutive event that effectively hands total control to a single investor, creating significant uncertainty for existing minority shareholders.

Positives

• Secured $6,000,000 in new capital funding from the investor.
• Clear leadership transition with the appointment of a new CEO and board designees.
• Shareholder approval obtained for critical capital structure changes and share conversions.

Negatives

• Extreme dilution of existing shareholders due to the issuance of 477,000,000 new shares.
• Concentration of power with a single individual holding 97.4% of the company's voting rights.

Risks

• Significant risk of minority shareholder disenfranchisement given the 97.4% ownership stake held by the Reporting Person.
• Potential for future volatility as the new controlling shareholder may increase or decrease his position.
• Dependence on the new CEO's strategy to improve the company's financial and operational performance.

Future Outlook

The Reporting Person intends to review his investment on a continuing basis and may engage in discussions regarding business combinations, dispositions, or changes to the company's capitalization and board structure to improve financial and operational performance.

Management Comments

• The Reporting Person believes the shares were undervalued and represented an attractive investment opportunity.
• The Reporting Person may in the future take actions including engaging in additional communications with management and the Board of Directors.

Industry Context

StockSavvy.ai notes that this transaction represents a 'take-private' style control shift via a massive equity issuance, which is highly unusual for a publicly traded entity and suggests a distressed or urgent need for capital and strategic restructuring.

Comparison to Industry Standards

• The 97.4% ownership concentration is significantly higher than typical institutional or activist investor stakes, which usually range from 5% to 20%.
• The dilution level is extreme compared to standard secondary offerings or private placements in the biotech sector.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Securities Purchase Agreement between the Issuer and David E. Lazar.

Stakeholder Impact

• Existing shareholders face extreme dilution of their equity interest.
• Minority shareholders have effectively lost voting control of the company.

Next Steps

• Ongoing review of investment by David E. Lazar.
• Potential future changes to board composition and company strategy.
• Possible future purchase or sale of shares by the Reporting Person.

Key Dates

Recommendation

The extreme dilution and concentration of control typically signal a negative outlook for existing minority shareholders, as the company's capital structure has been fundamentally altered to favor the new controlling investor.

Keywords

Mainz Biomed, David Lazar, Schedule 13D, Corporate Control, Shareholder Dilution, Biotech, Capital Raise